Look back at pharma news in the week to August 14, 2020

16 August 2020

By Barbara Obstoj-Cardwell. Editor

Last week’s notable regulatory news included the US Food and Drug Administration granting approval for Evrysdi (risdiplam), developed Roche by subsidiary Genentech and PTC Therapeutics, for the treatment of spinal muscular atrophy (SMA). Also, Russia has won the race to approve a vaccine against COVID-19, calling it Sputnik V. Moderna has been granted another government award for its COVID-19 vaccine, mRNA-1273. On the M&A front, Sweden’s Calliditas set out plans to acquire French firm Genkyotex, initially with a controlling equity stake and full acquisition thereafter.

Risdiplam approval adds to competitive intensity if SMA

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK